Desk
Background pieces that help the news make sense.
4 stories · latest 3 Nov 2026
The EXP desk holds the background pieces that make the daily wire easier to follow. They explain how to read a weight-loss trial headline, why some peptides sit outside the pharmacy, and how approval, compounding and patent rules shape what reaches patients.
Explainers are filed less often than news and are updated when the rules they describe change; the story log on each one records those changes. They link back to the news stories they help explain, and every claim in them points to a public record or an earlier story on this wire.
Developers at Arecor, WuXi AppTec and Sai Life Sciences told Pharmaceutical Technology that changing a peptide's structure can help it survive the gut, but each gain brings tradeoffs in potency, solubility and manufacturing.
UNITED STATES
An HHS policy lets pharmacies compound six unapproved peptides under set conditions, but BoxingInsider reports that all six remain banned in sport and a prescription is no defense for licensed fighters.
WASHINGTON · BoxingInsider report, 30 Oct 2026, on the HHS interim compounding enforcement policy published in the Federal Register on 30 Oct 2026
Two trials can report weight loss of 20% and mean very different things. Five questions sort out most of the confusion.
PEPTIDE ZONE DESK · Peptide Zone explainer; trial reporting conventions
A peptide with a huge online following has no approved product, a regulator flag for compounding and a place on the anti-doping list. Here is how each of those came about.
PEPTIDE ZONE DESK · FDA bulk drug substance lists; WADA Prohibited List
